A Rare Case of Tumor Lysis Syndrome
Anne Mainardi, Msiv, Daniel Okamoto, MD, Jianqing Lin, MD

INTRODUCTION
Tumor lysis syndrome (TLS) is a metabolic disturbance
caused by the destruction of rapidly dividing cancer cells
following administration of cytotoxic chemotherapy.
The subsequent release of intracellular material results
in hyperuricemia, hyperkalemia, hyperphosphatemia,
and hypocalcemia.1 The clinical presentation of TLS,
including acute kidney injury, results from these
electrolyte abnormalities and can be life-threatening.2
Here we present the second reported case of TLS in a
woman with endometrial cancer.

rate of 132 beats per minute and a respiratory rate
of 26 breaths per minute. She was noted to have a
harsh systolic murmur loudest at the right second
intercostal space and a mildly distended abdomen.
Chest radiography was unremarkable. A ventilation
perfusion scan was negative for pulmonary embolism.
Her labs at time of admission (Table 1) were consistent
with tumor lysis syndrome. Based on the Cairo-Bishop
criteria (described below), the diagnosis of tumor
lysis syndrome was made.

OUTCOME AND FOLLOWUP

CASE PRESENTATION
A 63 year old woman with newly-diagnosed
endometrial cancer (International Federation of
Gynecology and Obstetrics, FIGO, stage IVB) who
received her first dose of carboplatin and paclitaxel
four days earlier presented to the emergency room
with shortness of breath and lower extremity swelling.
Her physical examination was significant for a heart

The patient received vigorous intravenous hydration
with normal saline solution and treatment with
intravenous rasburicase. After two doses of rasburicase
her labs began to normalize (Table 1), and her symptoms
dissipated. On the day of discharge all lab abnormalities
had resolved, and the patient was discharged in stable
condition.

Table 1. Laboratory Values
Lab Parameter
(normal range at TJU)

Pre- chemotherapy

Admission

2 days after rasburicase

Serum potassium
(3.5-5.0 mmol/L)

4.4

5.5

4.5

BUN
(7-27 mg/dL)

14

68

65

Serum creatinine
(0.7-1.4 mg/dL)

0.8

2.4

1.9

Serum phosphate
(2.4-4.5 mg/dL)

n/a*

6.1

4.3

Serum calcium
(8.5-10.5 mg/dL)

n/a*

8.3

8.3

Serum Urate
(2.5-6.0 mg/dL)

n/a*

15

5.1

*values were not measured
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Table 2. Clinical Characteristics of Patients at High Risk for Tumor Lysis Syndrome
Tumors with a high proliferation rate and sensitivity to cytotoxic agents
Large tumor masses
Renal insufficiency and obstructive uropathy
Elevated serum lactate dehydrogenase or uric acid level
Dehydration

TABLE 3. Cairo-Bishop definition of laboratory tumor lysis syndrome in adults.
Diagnosis requires two or more of the following abnormalities observed within three days before to seven days after
initiation of chemotherapy:
Uric acid

Greater than or equal to 8.00 mg/dL or 25% increase from baseline

Potassium

Greater than or equal to 6.00 mmol/L or 25% increase from baseline

Phosphorous

Greater than or equal to 4.5 mg/dL or 25% increase from baseline

Calcium

Less than or equal to 7.0 mg/dL or 25% decrease from baseline

Table 4. Cairo-Bishop definition of clinical tumor lysis syndrome in adults.
Diagnosis requires meeting criteria of laboratory tumor lysis syndrome plus one or more of the following not directly or
probably attributable to a therapeutic agent:
1

Creatinine greater than 1.5 times upper limit of normal (our ULN = 1.4 mg/dL)

2

Cardiac arrhythmia/sudden death

3

Seizure

DISCUSSION
TLS is a rare but serious complication of cytotoxic
chemotherapy. Malignancies with the highest risk of
TLS are those with both high proliferative rates and
tumor burden, particularly hematologic malignancies.3
Solid tumors have a much lower incidence of TLS. A
literature review found the highest incidence of TLS
in small-cell carcinoma and breast carcinoma, with a
few reported cases each in neuroblastoma, germ cell
tumors, melanoma, and others.4 While a few cases of
TLS have been reported in association with gynecologic
cancers, 5,6 there has been only one reported case

associated with endometrial cancer. In this case from
2010, a 60 year old woman with recurrent FIGO
stage IIB endometrial cancer developed TLS four days
after receiving carboplatin and paclitaxel. The patient
required hemodialysis and expired despite aggressive
management.7
While TLS remains a rare complication of chemotherapy
in patients with solid tumors, the clinical characteristics
of patients at high risk for TLS should be recognized
(Table 2).8 In 2004, Cairo and Bishop proposed a system
for diagnosing and classifying tumor lysis syndrome.
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Table 3 describes the laboratory definition of TLS, and
Table 4 describes the clinical definition of TLS. Acute
kidney injury in TLS results from the release of nucleic
acids from lysed tumor cells, which are degraded by
xanthine oxidase to hypoxanthine, xanthine, and uric
acid. 9 In the acidic environment that often occurs
as a result of volume depletion, uric acid solubility
decreases10 and crystallization occurs in the distal tubules
and collecting ducts. This crystallization obstructs the
tubular lumen and leads to inflammation.11 Uric acid
may also contribute to acute kidney injury by crystalindependent mechanisms, due to its vasoconstrictive,
anti-angiogenic, pro-inflammatory, and pro-oxidative
properties.12 The other features of clinical tumor lysis
syndrome - tetany, cardiac arrhythmias, and seizures –
also result from the metabolic derangements that
occur when cancer cells are lysed by cytotoxic
chemotherapy.13 The patient described here did not
exhibit these manifestations.
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